Auvelity (AXS-05)
Major Depressive Disorder (MDD)
Key Facts
About Axsome Therapeutics
Axsome Therapeutics is a commercial-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for central nervous system (CNS) disorders. Founded in 2012, the company has transitioned from a development-focused entity to a revenue-generating commercial organization with three FDA-approved products: Auvelity (AXS-05) for MDD, Sunosi for narcolepsy/OSA, and Symbravo for migraine. Its core strategy leverages a differentiated platform focused on synergistic drug combinations and novel formulations to address significant unmet needs in psychiatry, neurology, and pain, driving a market valuation exceeding $8 billion.
View full company profileAbout Axsome Therapeutics
Axsome Therapeutics is a commercial-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for central nervous system (CNS) disorders. Founded in 2012, the company has transitioned from a development-focused entity to a revenue-generating commercial organization with three FDA-approved products: Auvelity (AXS-05) for MDD, Sunosi for narcolepsy/OSA, and Symbravo for migraine. Its core strategy leverages a differentiated platform focused on synergistic drug combinations and novel formulations to address significant unmet needs in psychiatry, neurology, and pain, driving a market valuation exceeding $8 billion.
View full company profileTherapeutic Areas
Other Major Depressive Disorder (MDD) Drugs
| Drug | Company | Phase |
|---|---|---|
| AL001 | Alzamend Neuro | Preclinical |
| Deep TMS (H1 Coil) | BrainsWay | FDA Cleared |
| EXXUA™ (gepirone ER) | Aytu BioPharma | Commercial |
| ZZ6398 | Zhongze Therapeutics | Phase 1/2 |
| INV-202 (Oral & LAI) | Indivior | Preclinical |
| NeuroStar Advanced Therapy | Neuronetics | FDA Cleared |
| Gepirone ER | Fabre-Kramer Pharmaceuticals | NDA Submitted |
| Exablate Neuro | Insightec | Clinical Trial |
| BrightKaire Platform for Depression | NeuroKaire | Pre-clinical |
| Tyemvers (CKDB-501) | Healis Therapeutics | Pre-clinical |
| VENTURA-7 | New Hope Clinical Research | Phase 2/3 |
| DT-101 | Draig Therapeutics | Phase 2 |